Oric raises $50M series C

Cancer company Oric Pharmaceuticals Inc. (South San Francisco, Calif.) said on Feb. 21 it raised $50 million in a series C round from new investors Fidelity Management & Research, Trinitas Capital, Taiho Ventures and NS Investment. Existing investors, including The Column Group, Topspin Fund, OrbiMed, Memorial Sloan Kettering Cancer Center, EcoR1 Capital, Kravis Investment Partners and Foresite Capital also participated. The company declined to disclose which investor led the round...